EISAI CO. LTD. ISIN: JP3160400002 WKN: 4523 Asset Class: Stock



Company Profile

Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.

Financial figures, Fiscal year: from 01.04. to 31.03.

	2023		2022		2021	
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	621,847,000,000		640,260,000,000		517,886,000,000	
Common stock capital		44,986,000,000		44,986,000,000		44,986,000,000
Fixed assets	641,503,000,000		599,055,000,000		572,123,000,000	
Equity capital of a company		822,571,000,000		771,533,000,000		727,942,000,000
Cash and cash equivalents	267,350,000,000		309,633,000,000		248,740,000,000	
Accrued liabilities		1,299,000,000		1,473,000,000		10,164,000,000
Other assets	-		-		-	
Current liabilities		298,945,000,000		313,333,000,000		256,017,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		141,834,000,000		154,448,000,000		106,050,000,000
Different income		-		-		-
Other liabilities		19,096,000,000		19,407,000,000		4,092,000,000
Total assets	1,263,350,000,000	1,263,350,000,000	1,239,315,000,000	1,239,315,000,000	1,090,009,000,000	1,090,009,000,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	11,076	11,322	11,237
Equity ratio	66.90%	64.09%	69.05%
Debt-equity ratio	49.48%	56.04%	44.81%

Others

	2023	2022	2021
Tax Expense Rate	-26.27%	16.05%	19.16%

EISAI CO. LTD.

ISIN: JP3160400002 WKN: 4523 Asset Class: Stock	ISIN:	JP3160400002	WKN:	4523	Asset Class:	Stock
---	-------	--------------	------	------	--------------	-------

Income statement 2023 2022 2021 Turnover 744,402,000,000 756,226,000,000 645,942,000,000 Net income 55,432,000,000 47,954,000,000 42,119,000,000 EBIT 260,195,500 332,248,700 319,902,300 52,551,000,000 Operating income before taxes 45,012,000,000 54,458,000,000 **Cash Flow** -1,772,000,000 117,590,000,000 73,853,000,000 Net interest income 2,357,000,000 -9,000,000 108,000,000 **Research and development expenses** 138,822,000,000 156,691,000,000 158,030,000,000 10,068,000,000 **Income taxes** -11,824,000,000 8,741,000,000 Result from investments in subsidaries, associates and other 0 0 **Revenues per employee** 409,972 407,435 350,649

Board of Directors

Clive Thornley	Member of Supervisory Board	
Fumihiko Ike	Member of Supervisory Board	
Hideki Hayashi	Member of Supervisory Board	
Hideyo Uchiyama	Member of Supervisory Board	
Hiroyuki Kato	Member of Supervisory Board	
Ryota Miura	Member of Supervisory Board	
Toru Moriyama	Member of Supervisory Board	
Yoshiteru Kato	Member of Supervisory Board	
Yuko Yasuda	Member of Supervisory Board	
Yumiko Miwa	Member of Supervisory Board	

Members of Management Board

Haruo Naito	Chairman of Managing Board
Akiko Nakahama	Member of Executive Committee
Gary Hendler	Member of Executive Committee
Ivan Cheung	Member of Executive Committee
Kazuhiko Tamura	Member of Executive Committee
Keisuke Naito	Member of Executive Committee
Kenta Takahashi	Member of Executive Committee
Lynn Kramer	Member of Executive Committee
Masatomi Akana	Member of Executive Committee
Mitsuo Kosaka	Member of Executive Committee
Mitsuru Shomon	Member of Executive Committee
Sayoko Sasaki	Member of Executive Committee
Shin Ujiie	Member of Executive Committee
Shohei Kanazawa	Member of Executive Committee
Takashi Owa	Member of Executive Committee
Tatsuyuki Yasuno	Member of Executive Committee
Terushige like	Member of Executive Committee
Teruyuki Masaka	Member of Executive Committee
Toshitaka Asano	Member of Executive Committee
Yanhui Feng	Member of Executive Committee
Yasushi Okada	Member of Executive Committee

0